Mr. Klein joins Crucell after having worked for almost three years at Koninklijke KPN N.V., where he successfully headed up the Intellectual Property group which included his involvement in major technology transfers and IP licensing. Mr. Klein also held previous positions as a patent attorney at Gist Brocades B.V. and Mogen International N.V. He has a background in molecular biology through his degree from Utrecht University, as well as being a registered Dutch and European patent attorney.

"We are delighted that Bart has accepted our offer to work for Crucell. Bart has extensive knowledge of many aspects of IP, which include licensing, protection and development. His expertise is crucial for us to strengthen these capabilities." commented Dinko Valerio, President and Chief Executive Officer for Crucell. "We are looking forward to working with Bart, and we are confident his experience will benefit Crucell immensely."

Crucell N.V. was formed in June 2000, through the merger of IntroGene B.V. and U-BiSys B.V., both from The Netherlands and listed on October 27, 2000 on both Nasdaq and Euronext Amsterdam. Crucell has two widely applicable technology platforms, a human cell line expression platform, PER.C6, and a subtractive phage antibody-display selection technology, called MAbstract, which provide a powerful and effective means to discover, develop and produce a variety of biopharmaceuticals for the treatment of human diseases, such as vaccines, human antibodies, therapeutic proteins and gene-therapy products. Crucell's technologies are fully human and, as such, enable biopharmaceuticals to be developed and produced that do not have the limitations inherent in many biopharmaceuticals currently available. Crucell has signed 15 license agreements for PER.C6 with major pharmaceutical and biotechnology companies. Crucell is investing in functional genomics through its joint venture with Belgian based Tibotec, called Galapagos Genomics. Crucell currently employs approximately 115 people in its facilities in Leiden, Utrecht and Leuven (Belgium).